Patent law

Biohaven and Royalty Pharma Announce Funding Agreement Totaling up to $450 Million

Retrieved on: 
Friday, August 7, 2020
Expense, Intellectual property law, Patent law, Royalty payment

Biohaven will receive $150 million at closing and $100 million upon the start of the oral zavegepant Phase 3 program.

Key Points: 
  • Biohaven will receive $150 million at closing and $100 million upon the start of the oral zavegepant Phase 3 program.
  • In return, Biohaven will pay to Royalty Pharma a series of equal fixed payments between 2025 and 2030 with an internal rate of return of approximately 12%.
  • Vlad Coric, M.D., Chief Executive Officer of Biohaven, commented, Royalty Pharma is an industry leader in funding innovative biopharmaceutical therapies and we are pleased to expand our partnership.
  • Forward-looking statements are based on managements current beliefs and assumptions and on information currently available to Royalty Pharma.

Nathan's Famous, Inc. Reports First Quarter Results

Retrieved on: 
Friday, August 7, 2020
Expense, Intellectual property law, Patent law, Royalty payment

License royalties increased to $10,523,000 during the first quarter fiscal 2021, as compared to $8,722,000 during the thirteen weeks ended June 30, 2019.

Key Points: 
  • License royalties increased to $10,523,000 during the first quarter fiscal 2021, as compared to $8,722,000 during the thirteen weeks ended June 30, 2019.
  • Sales from Company-operated restaurants were $1,934,000 during the first quarter fiscal 2021 compared to $4,124,000 during the thirteen weeks ended June 30, 2019.
  • Revenues from franchise operations were $191,000 during the first quarter fiscal 2021, compared to $1,077,000 during the thirteen weeks ended June 30, 2019.
  • Total franchise fee income was $81,000 during the first quarter fiscal 2021 compared to $97,000 during the thirteen weeks ended June 30, 2019.

10x Genomics to Participate in the UBS Genomics 2.0 and Medtech Innovations Summit

Retrieved on: 
Thursday, August 6, 2020
Monopoly, Branches of biology, 10x Genomics, Patent law, Zimmer Biomet Robotics, Patent portfolio, NASDAQ, Patent, Genomics, Biology, Companies

PLEASANTON, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit.

Key Points: 
  • PLEASANTON, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- 10x Genomics (Nasdaq: TXG) today announced the company will be participating in the upcoming UBS Genomics 2.0 and Medtech Innovations Virtual Summit.
  • 10x Genomics management is scheduled to participate in a fireside chat on Wednesday, August 12 at 8:00 a.m. Pacific Time / 11:00 a.m. Eastern Time.
  • The companys integrated solutions include instruments, consumables and software for analyzing biological systems at a resolution and scale that matches the complexity of biology.
  • The company's patent portfolio comprises more than 740 issued patents and patent applications.

XOMA Reports Second Quarter 2020 Financial Results

Retrieved on: 
Thursday, August 6, 2020
Expense, Intellectual property law, Patent law, Royalty payment, Emeryville, California, Geography of California

EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), today announced its second quarter 2020 royalty asset portfolio advancements and financial results.

Key Points: 
  • EMERYVILLE, Calif., Aug. 06, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA), today announced its second quarter 2020 royalty asset portfolio advancements and financial results.
  • XOMA recorded total revenues of $0.4 million for the second quarter of 2020, compared with $1.0 million recorded for the second quarter of 2019.
  • Research and development expenses were $0.04 million for the second quarter of 2020, compared to $0.7 million for the second quarter of 2019.
  • Net loss for the second quarter of 2020 was $3.5 million, compared to $4.1 million for the second quarter of 2019.

InventHelp Inventor Develops Improved Tree Stand/Shelter for Hunters (NMJ-305)

Retrieved on: 
Thursday, August 6, 2020
Tree stand, Patent, Patent law

The patent-pending invention provides an improved tree stand/shelter option for hunters.

Key Points: 
  • The patent-pending invention provides an improved tree stand/shelter option for hunters.
  • As a result, it saves time and effort and it could enhance safety, comfort and accessibility.
  • The invention features a portable and effective design that is convenient and easy to use so it is ideal for hunters, older sportsmen and individuals with physical limitations.
  • "My design enables anyone to safely access and use a tree stand without the risk of falling."

InventHelp Inventor Presents a Vehicle Lifting Jack Accessory (MTN-3439)

Retrieved on: 
Thursday, August 6, 2020
Geography of Pennsylvania, Lifting equipment, Human behavior, Patent law, Pittsburgh, Pittsburgh metropolitan area, Jack, Inventor, Invention, Humans

PITTSBURGH, Aug. 6, 2020 /PRNewswire/ -- An inventor from New York, N.Y., wanted to fulfill the need for an improved vehicle jack lifting or cable hoisting accessory.

Key Points: 
  • PITTSBURGH, Aug. 6, 2020 /PRNewswire/ -- An inventor from New York, N.Y., wanted to fulfill the need for an improved vehicle jack lifting or cable hoisting accessory.
  • It eliminates manual labor and the need for assistance from a second person.
  • My invention allows me to work on my bike in tight spaces comfortably," said the inventor.
  • InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.

Acceleron Announces Second Quarter 2020 REBLOZYL® Net Sales

Retrieved on: 
Thursday, August 6, 2020
Biotechnology, General Health, Pharmaceutical, Health, Expense, Intellectual property law, Patent law, Royalty payment

Acceleron expects to report royalty revenue of approximately $11.1 million from net sales of REBLOZYL in the United States for the second quarter ended June 30, 2020.

Key Points: 
  • Acceleron expects to report royalty revenue of approximately $11.1 million from net sales of REBLOZYL in the United States for the second quarter ended June 30, 2020.
  • This compares with approximately $1.5 million in royalty revenue from approximately $8.0 million of net sales of REBLOZYL in the United States for the first quarter ended March 31, 2020.
  • Acceleron will announce its full second quarter 2020 financial and operating results after the close of the U.S. financial markets today, August 6, 2020.
  • The Company will host a webcast and conference call to discuss its second quarter 2020 financial results and provide an update on recent corporate activities on August 6, 2020, at 5:00 p.m. EDT.

Athenex Announces $50 Million Revenue Interest Financing with Sagard Healthcare Royalty Partners

Retrieved on: 
Thursday, August 6, 2020
Carbonyl compounds, Organic compounds, Oxygen compounds, Expense, Intellectual property law, Patent law, Royalty payment, Paclitaxel, Oaktree

In exchange for funding this capital, SHRP will receive a temporary mid-single digit royalty on net sales of Oral Paclitaxel.

Key Points: 
  • In exchange for funding this capital, SHRP will receive a temporary mid-single digit royalty on net sales of Oral Paclitaxel.
  • We are delighted to have Sagard Healthcare Royalty Partners as another financial partner, as Athenex continues to make excellent progress towards our goal of bringing important novel cancer therapies like Oral Paclitaxel to patients, said Dr. Johnson Lau, Chairman and Chief Executive Officer of Athenex.
  • We believe that this Revenue Interest Financing transaction is precedent setting in that it would provide $50 million of additional non-dilutive capital that co-exists with the covenant-light, 6-year $225 million senior term debt provided by Oaktree.
  • Revenue Interest Financing is becoming an increasingly attractive option for innovative companies such as Athenex as they look to commercialize novel therapies.

Conformis Reports Second Quarter 2020 Financial Results and Announces Planned Portfolio Expansion Targeted at Ambulatory Surgical Centers

Retrieved on: 
Wednesday, August 5, 2020
Kosciusko County, Indiana, Economy of Indiana, Companies, Expense, Intellectual property law, Patent law, Royalty payment, BlackBerry Limited, License, Biomet, INDIANA

Total revenue in each of the second quarter of 2020 and 2019 includes royalty and licensing revenue of $9.7 million and $0.3 million, respectively, related to patent license agreements.

Key Points: 
  • Total revenue in each of the second quarter of 2020 and 2019 includes royalty and licensing revenue of $9.7 million and $0.3 million, respectively, related to patent license agreements.
  • The increase in royalty revenue in the second quarter of 2020 compared to the same quarter in the prior year is primarily due to the patent license settlement of $9.6 million due from Zimmer Biomet.
  • Conformis Hip System sales in the second quarter of 2020 were up 12.0% to $0.6 million, which were all in the United States.
  • Total gross profit increased $1.4 million to $11.0 million, or 57% of revenue, in the second quarter of 2020, compared to $9.6 million, or 49% of revenue, in the second quarter of 2019.

InventHelp Inventor Develops Accessory to Protect Against Underarm Perspiration (TRO-311)

Retrieved on: 
Wednesday, August 5, 2020
Patent law, Human behavior, Axilla, Humans, Inventor, Patent, Invention, Articles

The patent-pending invention provides added protection against underarm perspiration and its odor.

Key Points: 
  • The patent-pending invention provides added protection against underarm perspiration and its odor.
  • As a result, it could increase comfort and confidence and it provides added peace of mind.
  • The inventor described the invention design.
  • 19-TRO-311, InventHelp, 217 Ninth Street, Pittsburgh, PA 15222, or call (412) 288-1300 ext.